{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:54:48Z","timestamp":1781200488317,"version":"3.54.1"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"13","funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer.\n            <jats:bold>Methods:<\/jats:bold>\n            A Bayesian fixed-effects indirect treatment comparison (ITC) analysis was performed to simulate the comparative efficacy (primary outcome of progression-free survival [PFS]) and safety of PARP inhibitor monotherapy.\n            <jats:bold>Results:<\/jats:bold>\n            ITC of data from the OlympiAD (olaparib) and EMBRACA (talazoparib) studies suggested no significant difference in efficacy (PFS) between olaparib and talazoparib. However, there were differences in specific adverse events; patients receiving olaparib had a higher rate of nausea and vomiting, while those receiving talazoparib had a higher rate of alopecia and anemia.\n            <jats:bold>Discussion:<\/jats:bold>\n            These data support the benefit of the PARP inhibitor class in gBRCAm HER2-negative metastatic breast cancer.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0097","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T10:05:31Z","timestamp":1625652331000},"page":"1021-1030","source":"Crossref","is-referenced-by-count":12,"title":["Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer"],"prefix":"10.57264","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4122-4268","authenticated-orcid":false,"given":"Charles","family":"McCrea","sequence":"first","affiliation":[{"name":"AstraZeneca, Academy House, 136 Hills Road, Cambridge\u00a0CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hettle","sequence":"additional","affiliation":[{"name":"AstraZeneca, Academy House, 136 Hills Road, Cambridge\u00a0CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Gulati","sequence":"additional","affiliation":[{"name":"AstraZeneca, Academy House, 136 Hills Road, Cambridge\u00a0CB2 8PA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Taneja","sequence":"additional","affiliation":[{"name":"BresMed, 906-912, JMD Megapolis, Sohna Road, Gurugram, Haryana\u00a0122018, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preety","family":"Rajora","sequence":"additional","affiliation":[{"name":"BresMed, 906-912, JMD Megapolis, Sohna Road, Gurugram, Haryana\u00a0122018, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"16","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","article-title":"Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years","volume":"66","author":"Malone KE","year":"2006","unstructured":"Malone KE, Daling JR, Doody DR Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66(16), 8297\u20138308 (2006).","journal-title":"Cancer Res."},{"issue":"4","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1055-9965.EPI-08-1090","article-title":"Performance of prediction models for BRCA mutation carriage in three racial\/ethnic groups: findings from the Northern California Breast Cancer Family Registry","volume":"18","author":"Kurian AW","year":"2009","unstructured":"Kurian AW, Gong GD, John EM Performance of prediction models for BRCA mutation carriage in three racial\/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 18(4), 1084\u20131091 (2009).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"e_1_3_4_5_2","unstructured":"ACS. Breast Cancer Facts and Figures (2018). www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2017-2018.pdf"},{"key":"e_1_3_4_6_2","unstructured":"SEER. Breast Cancer Facts (2019). https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"issue":"23","key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker KB","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23), 2402\u20132416 (2017).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck N","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J Breast cancer. Nat. Rev. Dis. Primers 5(1), 66 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"4","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in cancer","volume":"60","author":"O'Connor MJ","year":"2015","unstructured":"O'Connor MJ. Targeting the DNA damage response in cancer. Mol. Cell. 60(4), 547\u2013560 (2015).","journal-title":"Mol. Cell."},{"issue":"6","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377(6), 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson ME","year":"2019","unstructured":"Robson ME, Tung N, Conte P OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30(4), 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"issue":"9","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon KA","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9), 852\u2013861 (2011).","journal-title":"Lancet Oncol."},{"issue":"8","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton JK","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379(8), 753\u2013763 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton JK","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31(11), 1526\u20131535 (2020).","journal-title":"Ann. Oncol."},{"issue":"15","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083","volume":"23","author":"Somlo G","year":"2017","unstructured":"Somlo G, Frankel PH, Arun BK Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin. Cancer Res. 23(15), 4066\u20134076 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized Phase II study","volume":"29","author":"Han HS","year":"2018","unstructured":"Han HS, Dieras V, Robson M Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized Phase II study. Ann. Oncol. 29(1), 154\u2013161 (2018).","journal-title":"Ann. Oncol."},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (2019). www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_4_18_2","unstructured":"NICE. Single Technology Appraisal: user guide for company evidence submission template (2017). www.nice.org.uk\/process\/pmg24\/chapter\/instructions-for-companies"},{"issue":"3","key":"e_1_3_4_19_2","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"3","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 3(3), e123\u2013e130 (2009).","journal-title":"Open Med."},{"issue":"4","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, Phase 3 trial","volume":"16","author":"Hu XC","year":"2015","unstructured":"Hu XC, Zhang J, Xu BH Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, Phase 3 trial. Lancet Oncol. 16(4), 436\u2013446 (2015).","journal-title":"Lancet Oncol."},{"issue":"5","key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial","volume":"24","author":"Tutt A","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat. Med. 24(5), 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"e_1_3_4_22_2","unstructured":"FDA. LYNPARZA (Olaparib) Prescribing Information (2014). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208558s014lbl.pdf"},{"key":"e_1_3_4_23_2","unstructured":"FDA. TALZEENA (Talazoparib) Prescribing Information (2018). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211651s000lbl.pdf"},{"issue":"3","key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","article-title":"Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the Phase III EMBRACA trial","volume":"25","author":"Hurvitz SA","year":"2019","unstructured":"Hurvitz SA, Goncalves A, Rugo HS Talazoparib in patients with a germline BRCA-mutated advanced breast cancer: detailed safety analyses from the Phase III EMBRACA trial. Oncologist 25(3), e439\u2013e450 (2019).","journal-title":"Oncologist"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2019.06.023","article-title":"Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial","volume":"120","author":"Robson M","year":"2019","unstructured":"Robson M, Ruddy KJ, Im SA Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur. J. Cancer 120, 20\u201330 (2019).","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai J","year":"2014","unstructured":"Murai J, Huang SY, Renaud A Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13(2), 433\u2013443 (2014).","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"e_1_3_4_27_2","article-title":"A novel assay for PARP-DNA trapping provides insights into the mechanism of action (MoA) of clinical PARP inhibitors (PARPi)","volume":"79","author":"Illuzzi G","year":"2019","unstructured":"Illuzzi G, O'Connor M, Leo E. A novel assay for PARP-DNA trapping provides insights into the mechanism of action (MoA) of clinical PARP inhibitors (PARPi). Cancer Res. 79(Suppl. 13), abstract 2077 (2019).","journal-title":"Cancer Res."},{"issue":"1","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"PARP-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice","volume":"122","author":"Farres J","year":"2013","unstructured":"Farres J, Martin-Caballero J, Martinez C PARP-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice. Blood 122(1), 44\u201354 (2013).","journal-title":"Blood"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.1016\/j.jval.2019.09.403","article-title":"Cost comparison of adverse event management with poly(ADP-ribose) polymerase (PARP) inhibitors or chemotherapy in gBRCA-mutated, HER2-negative advanced breast cancer (ABC): a US and German healthcare perspective","volume":"22","author":"McCrea C","year":"2019","unstructured":"McCrea C, MacDonald D, Hettle R Cost comparison of adverse event management with poly(ADP-ribose) polymerase (PARP) inhibitors or chemotherapy in gBRCA-mutated, HER2-negative advanced breast cancer (ABC): a US and German healthcare perspective. Value Health 22, S476 (2019).","journal-title":"Value Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:57:24Z","timestamp":1679230644000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.2217\/cer-2021-0097"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0097","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}